Clinical Trials Logo

Filter by:
NCT ID: NCT06450925 Not yet recruiting - Clinical trials for Vitamin D Deficiency

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

Start date: October 2024
Phase: N/A
Study type: Interventional

The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.

NCT ID: NCT06450912 Completed - Clinical trials for Acute Myocardial Infarction

Wall Strain Index Ratio as a Biomarker for Mechanical Complication of Hemorrhagic Myocardial Infarction

MIRON-STRAIN
Start date: June 1, 2022
Phase:
Study type: Observational

Hemorrhagic Myocardial infarctions are at high risk for mechanical complications including cardiac rupture. Prediction of vulnerable myocardial segments is an important step for the stratification of hemorrhagic MI patients. Wall motion index ratio is an important parameter to determine regions of high vulnerability within the 17-segment LV model of hemorrhagic MI.

NCT ID: NCT06450899 Recruiting - Clinical trials for Acute Mountain Sickness

Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

Start date: August 2024
Phase: Phase 2
Study type: Interventional

This study is a trial looking at a drug to help prevent acute mountain sickness. The drug is prochlorperazine, a drug commonly used to treat nausea vomiting and headache. Participants will either take the drug or a placebo, and hike to and sleep at the summit of Mount Blue Sky located at 4,348 meters (14,265 feet).

NCT ID: NCT06450873 Not yet recruiting - Clinical trials for HER2-Negative Breast Carcinoma

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. Giving TTM may be effective in treating post-menopausal women with HER2-negative, ER-positive breast cancer undergoing surgery.

NCT ID: NCT06450860 Recruiting - Food Insecurity Clinical Trials

Developing a Nutrition Support Assessment Tool

NSAT
Start date: May 21, 2024
Phase: N/A
Study type: Interventional

The research team developed the Nutrition Support Assessment Tool (NSAT) that incorporates key patient life information (e.g., ability to cook, access to refrigerator/stove, medical conditions and nutritional status) to facilitate individualized nutrition referral. The overall goal of this study is to refine and test the NSAT as a systematic approach to provide individualized nutrition needs screening and referral for patients being discharged from the acute care setting at Jefferson Health. The investigators hypothesize the NSAT will be successful in identifying individualized nutrition referrals that are deemed acceptable and appropriate by enrolled participants.

NCT ID: NCT06450834 Not yet recruiting - Clinical trials for Postoperative Complications

Ostene in Thoracolumbar Decompression and Fusion Evaluated With VIBE

Ostene VIBe
Start date: June 2024
Phase:
Study type: Observational

In spine surgery, it is important to try to minimize bleeding. In particular, spine surgery often involves inserting hardware into bone, and/or removing bone in the spine. Because the bone in the spine contains blood vessels, there can often be bleeding from the bone itself that is difficult to stop completely. One way to stop bone bleeding is through the use of wax-like materials, which plug the bleeding bone and act as a physical barrier to stop bleeding. One example is Ostene bone hemostasis material, which has the advantage of being "water soluble", meaning it will dissolve naturally over time. The purpose of this study is to evaluate how well Ostene does at decreasing bleeding, by using a recognized scale called the validated intraoperative bleeding severity scale, abbreviated as "VIBe". In this study, the investigators will record the bleeding severity throughout multiple time points in surgery using this scale, and then the investigators will compare the measurements to patients in the past who did not receive Ostene. Overall, this research will help measure how well Ostene decreases bleeding.

NCT ID: NCT06450639 Not yet recruiting - Clinical trials for Duchenne Muscular Dystrophy

An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy

SHIELD DMD
Start date: September 30, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy (DMD) age ≥ 8 to < 16 years old receiving corticosteroid therapy.

NCT ID: NCT06450509 Recruiting - Down Syndrome Clinical Trials

Proactive Speech and Language Intervention for Infants With Down Syndrome

BBC-DS
Start date: February 28, 2024
Phase: N/A
Study type: Interventional

Children with Down syndrome (DS) face life-long struggles with verbal communication. Babble and speech sound development is delayed, and speech can be difficult to understand. Words emerge late, at 21 months on average, compared to 12 months for typical peers, and vocabulary and grammar can remain limited throughout adulthood. Because DS is diagnosed at or even before birth, these difficulties are predictable; yet despite this prognostic knowledge, systematic and sustained proactive interventions have not yet been developed: Most children with DS are not assessed and treated for speech and language delays until age 2 to 4 years. This presents an untapped opportunity space to conduct a clinical trial of a proactive intervention in earliest infancy with the goal of building resilience against the anticipated difficulties. The intervention trialed here is a modified version of Babble Boot Camp (BBC), a proactive speech and language intervention originally developed for young infants with classic galactosemia (CG) (NIH 5R01HD098253). CG is a metabolic disease that, similar to DS, is diagnosed at birth and poses risks for severe speech and language delays. BBC is implemented by a speech-language pathologist who, via telehealth, trains parents to incorporate skill-building activities and routines into their daily lives at home. For the present study, 20 children with DS age birth to 12 months will be recruited and randomized into two treatment arms. One group will receive weekly individualized parent sessions and close monitoring of the child's progress. The second group will receive the same content but at a lower intensity and dosage, via monthly parent group meetings. Both groups will receive their intervention for 10 months. Specific aims are to quantify benefits for babble, speech production, and receptive and expressive language and to investigate associations between conversational dynamics in child-adult interactions and the children's speech and language. Outcomes in speech and language skills will show relative feasibility and benefits for each of these treatment modalities and motivate a larger clinical trial, with the ultimate goal of changing the way infants with DS receive support in their speech and language development, from a deficit-based, remedial model to a proactive one.

NCT ID: NCT06450457 Not yet recruiting - Cerebellar Ataxia Clinical Trials

Effects of High Intensity Stepping Training on Gait in Patients With Ataxia

Start date: June 10, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effects of high intensity stepping training on gait outcome measures in patients with cerebellar ataxia, to identify the correlations between gait outcome measures and measures of ataxia and balance in individuals with cerebellar ataxia and to determine differences in response to high intensity stepping training based off of diagnosis.

NCT ID: NCT06450405 Not yet recruiting - Transgenderism Clinical Trials

Androgen Effects on the Reproductive Neuroendocrine Axis

Start date: June 1, 2024
Phase:
Study type: Observational

This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.